1 / 2FUJIFILM Wako HCC Risk Biomarkers (AFP-L3 & DCP)
Manufacturer: Fujifilm · Origin: Japan
SKU: KES-ASSAY-DETECTION-FUJI-HCC-BIOMARKERS · Model: AFP-L3 / DCP
In vitro diagnostic serum biomarkers for hepatocellular carcinoma (HCC) risk assessment in chronic liver disease.
Product Overview
FUJIFILM Wako's HCC risk biomarkers AFP-L3 and DCP are intended for in vitro diagnostic use as an aid in the risk assessment of patients with chronic liver disease for the development of hepatocellular carcinoma (HCC), supporting early liver cancer detection programmes. Supplied by KRIMS Meditech Solutions with installation, commissioning, application training and maintenance support across Africa.
Applications
Hepatology clinics, liver cancer screening programmes, clinical laboratories.
Clinical Benefits
Improved diagnostic accuracy, enhanced patient safety, and reduced operational downtime.
Key Features
AFP-L3 and DCP assays; HCC risk assessment; supports early detection programmes.
Technical Specifications
Verified against the official FUJIFILM Healthcare product page. Detailed configuration options and technical specifications available from KRIMS on request.
Downloads
Commercial Information
Frequently Asked Questions
Equipment guide in the Knowledge Centre
Read our guide to the FUJIFILM Wako HCC Risk Biomarkers (AFP-L3 & DCP): what it is used for, key features, technical considerations and purchasing guidance.
